Emergent BioSolutions (EBS) PT Lowered to $75 at Chardan Capital Markets
Tweet Send to a Friend
Chardan Capital Markets analyst Keay Nakae lowered the price target on Emergent BioSolutions (NYSE: EBS) to $75.00 (from $92.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
